<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923427</url>
  </required_header>
  <id_info>
    <org_study_id>266-SBKAEK</org_study_id>
    <nct_id>NCT02923427</nct_id>
  </id_info>
  <brief_title>I-gel vs LMA Supreme in Laparoscopic Gynecological Surgery</brief_title>
  <official_title>Comparison of I-gel and LMA Supreme Without Neuromuscular Blocker in Laparoscopic Gynecological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of i-gel and Laryngeal mask airway Supreme (LMA-Supreme) on
      ventilation parameters and surgical view during Trendelemburg Position laparoscopic
      gynecological surgery in cases administered positive pressure ventilation without the use of
      neuromuscular agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized and double-blind study, aged from 18 to 65 years undergoing elective
      laparoscopic gynecological surgery.

      The patients are randomly assigned to 2 groups:

        -  Group 1: i-gel

        -  Group 2: LMA- Supreme

      Procedure:

      The investigation protocol contains the following sections:

        1. Induction of anaesthesia. For preoperative sedation 0.02 mg/kg midazolam IV will be
           administered. 2 minutes of 0.2 µ/kg/min remifentanil and 6 mg kg st-1 propofol infusion,
           IV 1-2 mg kg-1 propofol . No muscle relaxant will be used for insertion of the airway
           device.

        2. Bispectral index values will be held between 40-60.Bispectral index values will be
           within this interval by increasing or decreasing propofol infusion by 1 mg/kg after
           additional bolus dose of propofol (1 mg/kg).

        3. Insertion of the airway device. The size of the airway device used is based on the
           manufacturers' recommendations. All devices are deflated a lubricated prior to use. Once
           inserted, the cuff is be inflated with a manometer up to 60 cm H20 Data recorded: size
           of airway device, time an number of attempts.

        4. Anesthesia maintenance will be ensured by 50% O2/air with 0.1-0.4 µ kg/min-1
           remifentanil and 50-150 µ kg/ min-1 (4-10 mg/kg/hr) propofol IV infusion

        5. Functionality of the gastric drainage channel of the airway device: passage of a 14 G
           size tube.

        6. Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and
           at 2 minutes after airway device insertion (T1), 10 minutes after insufflation (T2),
           before desufflation (T3), before removal of airway device (T4). The maximum pressure
           allowed is 40 cm H2O.

        7. Ventilatory mechanics and parameters and hemodynamic parameters are measured at
           baseline, and at T1, T2, T3 and T4.

        8. Perioperative complications: Cough, vomiting, laryngeal spasm, laryngeal Stridor, airway
           intervention requirements, hypoxia (SpO2 &lt; 92%)

        9. Removal of the airway device: Presence of blood - 3 level grading (1:no blood; 2: trace
           amounts of blood; 3: clear amounts of blood). Complications: sore throat ( VAS:10-point
           scale), dysphonia (yes/no), dysphagia (yes/no).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Airway seal pressure values</measure>
    <time_frame>At baseline and at 15, 30 and 60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual quality</measure>
    <time_frame>during pneumoperitoneum</time_frame>
    <description>quality of surgical view will be assessed with points from 1 to 4 by the surgeon blind to the airway device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric tube insertion</measure>
    <time_frame>following airway device insertion up to 5 minutes</time_frame>
    <description>Ease of passage of a gastric tube as: very easy, easy, difficult or very difficult</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pharyngolaryngeal morbidity</measure>
    <time_frame>postoperative 1th hour and 24th hour</time_frame>
    <description>sore throat (10 point scale, VAS), dysphonia (yes/no), dysphagia (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sufficiency of pneumoperitoneum</measure>
    <time_frame>baseline</time_frame>
    <description>Sufficiency of pneumoperitoneum for the surgical procedure according to surgeon, described as sufficient or insufficient questionaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean airway pressure values</measure>
    <time_frame>At baseline and at 15, 30 and 60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Airway Morbidity</condition>
  <condition>Anaesthesia</condition>
  <arm_group>
    <arm_group_label>Laryngeal mask Supreme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of the &quot;Laryngeal mask Supreme&quot; and evaluation of its clinical performance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>i-gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insertion of the &quot;i-gel&quot; and evaluation of its clinical performance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laryngeal mask Supreme Evaluation</intervention_name>
    <description>Evaluation of clinical performance in terms of Insertion, ventilation and complications</description>
    <arm_group_label>Laryngeal mask Supreme</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>i-gel Evaluation</intervention_name>
    <description>Evaluation of clinical performance in terms of Insertion,ventilation and complications</description>
    <arm_group_label>i-gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. American Society of Anesthesiologists classification group I-II

          2. between 18-65 years

          3. undergoing elective laparoscopic gynecological surgery

        Exclusion Criteria:

          1. Those with any neck or upper respiratory tract pathology

          2. Those at risk of gastric content regurgitation/aspiration (previous upper
             Gastrointestinal system surgery, known hiatus hernia, gastroesophageal reflux, history
             of peptic ulcers, full stomach, pregnancy)

          3. Those with low pulmonary compliance or high airway resistance (chronic pulmonary
             diseases)

          4. Obese patients (BMI &gt;35)

          5. Those with throat pain, dysphagia and dysphonia

          6. Those with possible or previous difficult airway

          7. Those with operations planned for longer than 4 hours

          8. Conversion to laparatomy

          9. Neuromuscular blocking agent used
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferim Günenç, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sule Ozbilgin, MD</last_name>
    <phone>+902324122801</phone>
    <email>ozbilginsule@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ferim Günenç, MD</last_name>
    <phone>+902324122801</phone>
    <email>ferimgunenc@deu.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation</name>
      <address>
        <city>İzmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sule Ozbilgin, MD</last_name>
      <phone>+902324122801</phone>
      <email>ozbilginsule@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gözde Altuntaş Uzun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferim Günenç, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sule Ozbilgin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bahar Kuvaki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Semih Küçükgüçlü, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Sule Ozbilgin</investigator_full_name>
    <investigator_title>Dokuz Eylul University, MD, Anesthesiologists.</investigator_title>
  </responsible_party>
  <keyword>laryngeal mask Supreme</keyword>
  <keyword>i-gel</keyword>
  <keyword>laparoscopic gynecological surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 21, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

